Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2026 CLL Highlights
02 July 2026 | Virtual Meeting
Post-EHA 2026 CLL Highlights
Featuring presentations & discussions on selected CLL abstracts from the 31st Congress of the European Hematology Association (EHA).
Chair: Alexey Danilov | Moderators: Othman Al-Sawaf, Catherine Coombs & Deborah Stephens
The Post-EHA 2026 CLL Highlights has been supported by AstraZeneca (Diamond Sponsor), Genentech (Silver Sponsor), and Nurix (Silver Sponsor). Supporters have no influence over the production of content.
Session 1: Advances with BTKis and BTK degraders
Final results from ASSURE: A Phase 3B study of the safety and efficacy of acalabrutinib in patients with chronic lymphocytic lymphoma
Carsten Niemann Copenhagen University Hospital, Copenhagen, Denmark
Outcomes of venetoclax-based treatment in patients with Bruton tyrosine kinase inhibitor (BTKI)-treated chronic lymphocytic leukemia (CLL): An international study conducted by ERIC
Thomas Chatzikonstantinou Center for Research and Technology Hellas , Thessaloniki, Greece
Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314
Jennifer Woyach The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States
Updated efficacy and safety data from an ongoing Phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy
Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL): A Phase 1 CADANCE-101 study update
Stephan Stilgenbauer Ulm University, Ulm, Germany
Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated CLL/SLL: a Phase 3, randomized trial (BRUIN CLL-322)
Matthew Davids Dana-Farber Cancer Institute, Boston, MA, United States
Panel discussion
Session 2: Updates in frontline combination strategies for CLL
A Phase 2 study of fixed-duration pirtobrutinib and obinutuzumab in previously untreated CLL
Inhye Ahn Dana-Farber Cancer Institute, Boston, MA, United States
First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53
Chan Yoon Cheah Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: final results of the randomized CLL14 study
Othman Al-Sawaf University Hospital of Cologne, Cologne, Germany
Panel discussion
Session 3: Latest with immunotherapy and cellular therapy in CLL
Fixed duration venetoclax plus epcoritamab shows favorable tolerability and high response rates with early molecular responses in R/R CLL/SLL: Interim analysis of the randomized HOVON 165/AETHER trial
Arnon Kater University of Amsterdam, Amsterdam, Netherlands
Dual targeted lentiviral transduced anti-CD20/anti-CD19 (LV20.19) CAR T-cells for relapsed/refractory CLL
Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States
Panel discussion
